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SUMMARY
Microbial resistance to chemotherapeutic agents is not a new develop-
ment: the first lactam hydrolyzing enzyme was identified before peni-
cillins were even introduced into the clinic. Extended-spectrum resistance
to the major classes of chemotherapeutic agents is now common across
many microorganisms, particularly pathogenic bacteria, and due in part
to over- and misuse of antibiotics over the last 50 years. Global travel
and greater social interaction has facilitated rapid transmission of in-
fectious diseases such as malaria, tuberculosis (TB), human immuno  -
deficiency virus (HIV) and hepatitis C virus (HCV), resulting in an
international agenda for addressing the lack of prevention and treat-
ment options for these diseases. This symposium brought together in-
ternational experts from the pharmaceutical industry and academia to
review the need for new antiinfective agents, present the latest thera-
peutic developments, and to discuss the challenges to be overcome in
the discovery and clinical development of novel antiinfective agents and
the development of new vaccines. Topics included novel approaches to
small-molecule discovery and development for the treatment of TB, HCV
and HIV, review of the vaccine approaches to meningitis and malaria,
and presentation of the new vaccines in clinical trials for their prevention.
Key words: Antibacterial agents – Antiviral agents – Tuberculosis –
HIV – Hepatitis C virus – Meningitis – Malaria
THE NEXT GENERATION OF ANTIBACTERIAL AGENTS
Global and clinical implications of multidrug- and 
pandrug-resistant Gram-negative bacteria
Professor Timothy Walsh, Cardiff University, U.K., opened the meet-
ing with a review of the discovery timeline for antibiotics in clinical
use, which has seen no new classes of agents licensed since 1987, and
the increasing incidence of resistance to antibacterial agents. Much
recent effort has focused on meticillin-resistant Staphylococcus au-
reus (MRSA) in the U.K., resulting in a steady decrease of incidence
levels, dropping from 40-50% in 2000-2005 to 14% in 2012, with
projections of a steady state of 10% over the next decade, although
this resistant pathogen remains at 40-50% in other countries, for ex-
ample Greece and Romania (1). However, it is the Gram-negative bac-
teria for which resistance is predicted to rise sharply over the next 30
years; resistance to cephalosporins and other b-lactams, including
carbapenems, in Escherichia coli, Pseudomonas aeruginosaand Kleb-
siella species is already rising. Since the discovery of Klebsiella pneu-
moniae carbapenemases (KPCs) in 1998, this particular mode of
resistance has spread across the globe, with a > 50% incidence in cer-
tain countries, e.g., Turkey and Greece. Perhaps of even greater threat,
the New Delhi b-lactamase NDM-1 was first noted in clinical cases
arising from the Indian subcontinent in 2002 and has since spread
steadily, not only across countries and continents, but also across bac-
terial species. The blaNDM-1 gene is carried on a plasmid, along with
the resistance genes for other antibacterial agents, and has been
identified in many countries and species; for example, E. coliin Japan,
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Acinetobacter baumanii in Germany. In the era of accessible global
travel, it should not be surprising that the rising spread of bacterial re-
sistance reflects the increased movement of travelers (2).
Despite the considerable number of articles in the press about its epi-
demiology, the prevalence of NDM-1, particularly in Northern India,
Bangladesh and Pakistan, where it appears to have originated, is un-
clear. The newly initiated charity South Asian Antibiotic Resistance
Research  Program  aims  to  harness  collaborations  between  re-
searchers in India, Bangladesh, Pakistan and the U.K. to evaluate the
incidence. So far, NDM-1 has been found across a wide range of En-
terobacteriaceae from hospital patient swabs, seepage water and
sewage. KPC spread worldwide to an incidence of about 14% in the 15
years since it was first identified; since 2002, NDM-1 has achieved an
incidence of > 40% and is still increasing in prevalence. In response
to the threat posed by increasing bacterial resistance to antibacterial
agents and aiming to tackle this global problem, the World Health
Organization (WHO) released an updated report in March 2012 — The
Evolving Threat of Antimicrobial Resistance: Options for Action (3).
However, the picture may not be as bleak as it first seems; people in-
fected with NDM-1-producing bacteria can be asymptomatic, indicat-
ing that such bacteria are not necessarily pathogenic. In the Galleria
mellonella (honeycomb moth) larvae model system, an inverse rela-
tionship was observed between virulence and resistance –in this
species at least, NDM-1-expressing E. coli did not cause high mortal-
ity (4), suggesting that most people would not be at risk of mortality
from infection by these resistant bacteria. If these observations were
borne out clinically, the major risk from these NMD-1-expressing bac-
teria would be for patients in intensive care, transplant patients and
other immunocompromised patients.
For the development of future antibacterial agents, a focus on Kleb-
siella and other pathogenic Gram-negative bacteria would offer a
greater clinical contribution. Furthermore, Klebsiella species appear
to acquire and spread resistance readily; tackling this species would
make an important contribution to the management of clinical bac-
terial infections.
Development of new drugs for resistant bacteria: the challenges
The emergence of multidrug-resistant bacteria is currently a major
world health problem. Hospital-acquired infections are becoming
more difficult to treat with a concomitant increase in mortality and
morbidity –25,000 attributable deaths in the E.U. in 2007. There is a
significant risk that in the relatively near future some regular medical
procedures may become impossible (e.g., hip replacement operations,
care of premature babies, chemotherapy).
Dr. Seamus O’Brien, AstraZeneca, U.K., discussed recent data demon-
strating the startling increase and unpredictable spread in drug-re-
sistant bacteria. This has made it very difficult to plan and conduct
clinical trials of agents targeting these bacteria using the classical
disease-focused pathways. The emergence, since the turn of the 21st
century, of carbapenem-resistant Enterobacteriaceae (CRE), and in
particular multidrug-resistant K. pneumoniae, is a major concern due
to the lack of effective antibacterials. Excellent data on the incidence
of carbapenem-resistant K. pneumoniae (CRKP) are available (2011
data) for most countries in Europe, and demonstrate significantly vari-
able rates, with the greatest incidence in South Eastern European
states (up to 50%), and a relatively low incidence in the U.K. (< 1%).
In recognition of this issue, the U.S. Centers for Disease Control and
Prevention (CDC) recently published new guidance (March 2013) for
the control of CREs.
There are three major challenges to the discovery and development
of new antibacterials, which have been factors in the reduced number
of major pharmaceutical corporations working on antibacterial re-
search in recent years. Firstly, various research challenges exist. For
example, antibacterials are structurally disparate to other pharma-
ceutical molecules and hence corporate archives used for high-
throughput screening (HTS) are relatively devoid of appropriate
chemotypes. Secondly, the clinical development environment, and in
particular the regulatory pathway, is very challenging. Thirdly, there
is currently a relatively low return on investment, as any new agents
would only be used as last-resort medications and may stay so
throughout their limited period of exclusivity. More recently, however,
there has been a worldwide awakening to the need to tackle the issue
of resistance with several high-profile U.S., E.U. and global initiatives.
A consortium of four pharmaceutical corporations has added to the
debate in this area by addressing novel approaches to antibacterial
clinical development and proposing the adaptation of existing regu-
latory frameworks to address the unmet need for new antibacterial
treatments (5).Key to these proposals is that regulatory frameworks,
including orphan drug and conditional approvals, recognize both the
extent of unmet medical needs and the feasibility of clinical studies in
the intended population to control the amount of data needed for
registration. The use of a new middle way to approval that focuses on
the pathogen rather than the site of infection would enable smaller
clinical studies supported by extensive preclinical packages, provid-
ing a “totality of evidence” approach to registration of antibacterials
for drug-resistant and rare pathogens. The aim is to avoid the para-
doxical situation of being forced in the future to accept even greater
degrees of therapeutic uncertainty as antimicrobial resistance pro-
gresses. Such changes to the regulatory environment are close; for
example, in July 2012 the European Medicines Agency released new
additional guidance for the development of antibacterials for public
consultation, and in October 2012 the U.S. Congress passed the Gen-
erating Antibiotic Incentives Now (GAIN) Act, which mandates the
FDA to develop guidelines for Limited Population Antibiotic Devel-
opment (LPAD) programs.
There is also an accepted need for public–private collaboration, as
arguably the challenges are too great for any single entity to solve.
An example of such collaboration is the Innovative Medicines Initia-
tive (IMI) – New Drugs4BadBugs (ND4BB) Programme. This has the
overall vision to create an innovative public–private partnership-based
approach to encompass all aspects from the discovery of new antibi-
otics to phase II and III clinical trials, with the aim of reinvigorating
antibiotic R&D. Some topics have now been agreed, including a con-
sortium –TRANSLOCATION– to improve the understanding of drug
permeability into Gram-negative bacteria. A second consortium
–COMBACTE– is tasked with improving the capability for antibiotic
clinical development through the creation of a clinical investigator
and laboratory networks, applying cutting-edge clinical trials and un-
dertaking therapeutic clinical trials. Additional topics for 2013 include
the discovery and early development of new drugs combating Gram-
negative infections.
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dustry realize the need to be faster and more flexible to develop new
antibiotics. This is beginning, but more is needed to reinvigorate the
discovery of targets and leads, improve clinical epidemiology and as-
sess new antibiotic business models.
Lessons learned in tuberculosis drug discovery
Dr. Jan Jiricek from the Novartis Institute for Tropical Diseases in Sin-
gapore presented recent results from their tuberculosis (TB) drug dis-
covery program. One-third of the world’s population is currently
infected with the TB bacillus, of which 5-10% become infectious at
some time during their life. People with HIV and TB infection are much
more likely to develop TB. There are 4,500 deaths/day because of TB.
Combinations of drugs are the mainstay of TB treatment, which con-
sists of 6-12 months of therapy. Multidrug-resistant (MDR) and ex-
tensively drug-resistant (XDR) cases are currently on the rise and
require second-line therapy, longer duration of treatment (approxi-
mately 2 years), have greater potential side effects and are 100-fold
more expensive. The cure rate for the treatment of MDR and XDR is
relatively poor (60% and 30%, respectively) and it has been 50 years
since the discovery of the most recent TB drug.
Dr. Jiricek gave an overview of current TB treatment options and their
challenges and then discussed the Novartis Institute for Tropical Dis-
eases (NITD) phenotypic TB drug discovery approach. Between 2006
and 2011, multiple HTS’s using phenotypic cellular-based assays were
performed and resulted in over 16,000 hit molecules. Applying vari-
ous chemical in silico filters, and the addition of compounds from a lit-
erature review, resulted in a reduced hit list of approximately 7,000
compounds. However, few hits were in ideal “lead-like” chemical
space (clogP < 4; Mol wt < 450), with a minimum inhibitory concen-
tration (MIC) of < 1 µM. Many of these hits contained familiar func-
tionality from the field of antibiotics and were eliminated from further
follow-up if they contained such a chemotype or had an anticipated
undesirable or nonspecific mechanism of action. This eventually re-
sulted in six lead series for further consideration.
Lead series 1 illustrated Dr. Jiricek’s first lesson: the importance of
growth medium in the in vitro assay conditions. Compound 3 (Figure
1), along with several other close analogues in series 1, showed po-
tent in vitro activity (MIC = 36 nM) and yet was totally inactive in an
acute mouse model of TB infection. Dr. Jiricek and colleagues (6)were
able to show that this was due to an in vitro assay artefact. Series 1,
unlike reference antibacterials, was dependent on glycerol (the spe-
cific carbon source used in the gold standard in vitro MIC assay),
whereas in vivo multiple carbon sources are available.
Dr. Jiricek then described an analysis of the physicochemical charac-
teristics of the validated lead series 2-6 in comparison with known TB
drugs. The major lessons learned here were that known TB drugs
mostly occupied a different chemical space to the lead series com-
pounds  and  the  lead  series  compounds  were  generally  of  high
lipophilicity (Figure 2). This latter property was anticipated to hinder
the development of such molecules due to their poor aqueous solu-
bility.
The challenges of optimizing the lead compounds towards candidate
molecules were described and illustrated with the imidazopyridine
series 2 compounds. In addition to the normal multiparameter opti-
mization issues associated with drug development, in the case of such
phenotypic screens, the lack of a well-defined molecular target adds
additional  challenges  to  gaining  an  understanding  of  the
structure–activity relationship (SAR).  In the case of series 2 com-
pounds, minor structural modification did deliver potent in vitro com-
pounds (MIC = 10 nM); however, in vivo assessment of bactericidal
activity demonstrated that the compounds were only effective as bac-
teriostatic agents. The goal of this work was to develop agents which
were effective bactericidal agents, and indeed, this was the final les-
son from Dr. Jiricek’s presentation, the need to focus quickly on the
chemotypes capable of killing the bacteria.
RECENT ADVANCES IN ANTIVIRAL AGENTS
Discovery and development of simeprevir (TMC-435) and 
TMC-647055, two novel direct antiviral agents targeting
hepatitis C virus
Dr. Pierre Raboisson, Janssen Infectious Deseases (Belgium), intro-
duced the challenges of hepatitis C virus (HCV) as a drug target and
described  the  discovery  process  leading  to  the  development  of
simeprevir. HCV infection is the number one leading cause of liver
transplant in the U.S. and is responsible for approximately two-thirds
of all liver transplants. HCV infection is responsible for between 50
and 75% of all liver cancers, having progressed from an initial acute
infection to hepatocellular carcinoma, and a health care burden that
is estimated to be several billion dollars worth per year. Approximately
3% of the world’s population is infected with HCV across the six major
genotypes, and the current standard of care (PEG-interferon alfa-2
and ribavirin combination, and the recently approved NS3 protease in-
hibitors telaprevir and boceprevir) is limited due to issues of toleration,
long duration of treatment (up to 48 weeks) and limited efficacy in
partial and null responders. This presentation described the drug dis-
covery program that was initiated by Tibotec (now Janssen) to iden-
tify novel direct-acting antivirals that were suitable for once-daily
dosing and could be incorporated into an enhanced-efficacy, inter-
feron-sparing regimen.
The first part of the presentation focused on the discovery and devel-
opment of TMC-435, a next-generation NS3(7, 8) protease inhibitor
that has recently been submitted for approval in Japan for the treat-
ment of HCV genotype 1 treatment-naive and nonresponder patients.
W.K. Alderton et al. SMR 2013
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Figure 1. Compound 3 and example of lead series 1.In a collaborative effort between Medivir and Tibotec, the published
NS3 protease noncovalent macrocyclic inhibitor BILN-2061 was trun-
cated and functional groups optimized to provide a lead acyl sulfon-
amide  that  was  a  potent  NS3  inhibitor  but  had  very  poor  oral
bioavailability in rats. Systematic optimization of the central cyclopen-
tane scaffold, the size and structure of the macrocyclic ring, the P2-
mimic heterocycle and isosteres of the P1 acidic acyl sulfonamide led
to the discovery of TMC-435 (simeprevir) (Figure 3), a potent and ef-
ficacious noncovalent NS3 protease inhibitor that was safe and well
tolerated in healthy volunteers and was shown to be suitable for once-
daily dosing. As monotherapy, 5-day treatment of TMC-435 200 mg
once daily produced a 4 log10 reduction in viral load and showed
equivalent efficacy against both genotypes 1a and 1b.
Dr. Raboisson also described a discovery program to identify macro-
cyclic inhibitors of the HCV NS5B polymerase based on a substituted
indole starting point. Several macrocyclic linkage designs were de-
veloped using structure-assisted hypothesis generation to identify a
candidate compound, TMC-647055, that binds to the thumb-1 do-
main of the HCV NS5B protein. Combination studies of various com-
pounds that targeted different viral proteins were carried out in
replicon-resistant cell lines, and showed that TMC-435 had an addi-
tive effect when combined with ribavirin or a non-nucleoside NS5B
inhibitor such as TMC-647055, but was synergistic when combined
with interferon or a nucleoside NS5B inhibitor. TMC-647055 has been
advanced into a phase Ib study in HCV-infected patients, and showed
an approximately 5-hour terminal half-life. Doses of up to 1000 mg
administered twice daily over 6 days to genotype 1b patients produced
up to 3.4 log10reductions in HCV RNA and similar levels of antiviral ef-
ficacy in genotype 1a patients. TMC-647055 was well tolerated and ef-
ficacy was found to be dose-dependent and related to plasma levels
of active component. It is currently being evaluated in phase II clini-
cal studies in combination with simeprevir and the cytochrome P450
CYP3A4 inhibitor ritonavir dosed once daily, with and without rib-
avirin, to patients chronically infected with HCV genotype 1.
Discovery of a novel allosteric mechanism for the regulation of
HCV NS3/4A protein using fragment screening and structure-
based design
Susanne Saalau-Bethell from Astex Pharmaceuticals, U.K., presented
a project that used fragment-based screening methods applied to the
full-length HCV NS3 protease to identify inhibitors that bound to a
novel and functionally relevant allosteric binding site. Fragment
screening offers a highly efficient means of sampling chemical space
against a target protein, and the Astex approach is built on their X-ray
crystallography platform. Using crystallography alongside alterna-
tive biophysical techniques, Astex screened the full-length HCV NS3
protease (a protein that comprises two domains, a helicase and a pro-
tease domain) with a small collection of 176 fragments. Hits were
identified as binding at one of three sites, including the RNA binding
groove and the ATP binding pocket, but most intriguing was a site lo-
cated at the junction of the two protein domains(9).  Some 16 frag-
ments were found that bound to this site, with binding affinities of
SMR 2013 W.K. Alderton et al.
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Figure 2. Log MIC vs. clogP for series 2-6 analogues and established TB drugs.between 5 mM and 100 µM and low to moderate ligand efficiencies.
They were confirmed active only to the full-length protein and not to
the protease domain alone. The working hypothesis that Astex devel-
oped was that the HCV NS3 protein could populate either an open
active state or a closed inactive state via a hinge-like movement of
the two linked domains. It was the latter state that was believed to
be stabilized by the fragment hits and was also sensitive to salt con-
centration in the buffer conditions used for protein preparation (10).
This interfacial binding site was found to be highly conserved across
HCV genotypes. Fragment optimization was carried out to provide
several leads with low micromolar or even submicromolar activity,
which were used to raise mutations in replicon cells that mapped to
the interfacial binding site, e.g., V630L. Two preclinical candidates
were eventually identified with low nM replicon cell-based potency,
excellent physicochemical properties and a predicted human dose of
between 300 and 600 mg. The structures of the preclinical candi-
date molecules have not yet been disclosed.
LEDGINs, a novel class of antivirals targeting HIV integration
Professor Zeger Debyser, KU Leuven (Belgium), started with a sum-
mary of the current HIV treatment strategies and the clinical inhibitors
with their targets, and then focused on integrase, its role in the HIV life
cycle and the current integrase inhibitors. The integrase strand trans-
fer inhibitors (INSTIs) raltegravir and elvitegravir are already licensed
for use, and a third agent, dolutegravir, is in clinical trials; all of these
agents inhibit strand transfer, resulting in a strong reduction in viral
load. However, resistance and cross-resistance between the mem-
bers of this class of agents has already been noted, and next-gener-
ation INSTIs are under development. To avoid the issue of increasing
resistance, new targets are required that do not show cross-resist-
ance with existing drugs.
Professor Debyser presented a rationale for a novel class of anti-HIV
agents targeted at cellular cofactors. These host-derived proteins are
hijacked by HIV proteins, such as integrase, and are essential to assist
the viral proteins in performing their function; agents designed to in-
hibit the interaction between proteins and their cofactor could reduce
the development of resistance, as these binding sites are likely to be
conserved. However, such targets are associated with specific chal-
lenges: protein–protein interactions are notoriously difficult to target
efficiently and inhibiting the interactions of a host protein could lead
to cellular toxicity. The group focused on the steps catalyzed by inte-
grase, particularly the transport of DNA into the nucleus and integra-
tion, using a workflow decision tree approach, which identified several
possible targets, such as LEDGF/p75 and transportin SR2. Validation
and characterization of the role of the targets, including co-immuno-
precipitation, knock down experiments, structural and cell biology,
led to LEDGF/p75 being identified as a suitable target (11, 12). Lens ep-
ithelium-derived growth factor (LEDGF) is a transcriptional coactiva-
tor involved in the normal mammalian cellular stress response; it is
hijacked by the HIV preintegration complex as a molecular tether for
the viral cDNA, as it is transported into the nucleus and inserted into
the host DNA. Through structure-based drug design, medicinal chem-
W.K. Alderton et al. SMR 2013
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Figure 3. Development of NS3 lead inhibitor to TMC-435 (simeprevir).
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Liver/plasma 32istry, structural biology and virology, a family of inhibitors was devel-
oped –the LEDGINs (Figure 4) (13).
Co-crystallization of a lead LEDGIN with LEDGF/p75 and HIV-1 inte-
grase confirmed that the inhibitor directly binds to the LEDGF/p75
binding pocket of HIV-1 integrase (hence the name), allosteric to the
active site, preventing the LEDGF/p75–integrase interaction; inhibi-
tion of integrase activity was also noted, despite their allosteric bind-
ing site (13). Development of further LEDGINs with structural diversity,
nanomolar potency and good selectivity for the integrase–LEDGF/p75
interaction (12, 14) allowed investigation into the mechanism of inte-
grase inhibition, showing that the LEDGINs stabilize the dimer form
of integrase in a concentration-dependent manner, which interferes
with catalytic activities (14, 15). Furthermore, LEDGINs decrease the in-
fectivity of HIV viral progeny, results that may indicate a role for
LEDGF/p75 in virion assembly (14).
The LEDGINs exhibit activity across a broad range of HIV-1 subtypes
and display no cross-resistance with other integrase inhibitors; in fact,
additive to synergistic activity was shown for lead compound CX-
14442 with the integrase inhibitor raltegravir, with no antagonism (14).
Thus, the LEDGINs represent a novel class of antiretroviral (ARV)
agents, with a novel and multimodal mechanism of action, synergis-
tic with existing ARVs, and with the potential to make an important
contribution to the future treatment of HIV.
ADVANCES IN VACCINES TARGETING INFECTIOUS DISEASE
Advances in meningococcal vaccine research
Dr. Peter Dull, Head of Development Meningitis and Sepsis Vaccines,
Novartis Vaccines and Diagnostics (Novartis, U.S.), gave an overview
of the development of 4CMenB (Bexsero®), a serogroup B meningo-
coccal disease vaccine. Meningococcal disease (meningitis) is a sud-
den, unpredictable and potentially fatal disease which typically occurs
in otherwise healthy people without identified risk factors. Early symp-
toms are flu-like before rapid progression to death within 24 to 48
hours, with hospitalization only usually when late-stage symptoms
appear at, on average, 19 hours. Meningococcal disease can lead to
significant morbidity and mortality among adolescents (15-24 years)
and infants (0-4 years), where 5 to 15% of cases are fatal and 11 to
19% of survivors have significant sequelae, such as amputations, deaf-
ness and neurological defects. A successful vaccination campaign
against serogroup C meningococcal disease in the U.K. in 1999 led to
its rapid decline and near eradication. Similarly, vaccines have dra-
matically reduced Haemophilus influenzae type b and pneumococcal
disease rates where the vaccines were widely implemented from the
mid-1980s to the early 2000s. However, serogroup B meningococcal
disease (MenB) remains a significant medical need and alternative
vaccine strategies have been required to address it. Glycoconjugate
vaccines against meningitis-causing pathogens have been successful
by utilizing the polysaccharide capsule; however, in the case of MenB,
the capsule was found to be nonimmunogenic. Therefore, Novartis
adopted  an  innovative,  genomic-based  approach  to  identifying
broadly conserved protein antigens which induce bactericidal anti-
bodies through a process called “reverse vaccinology”. The complete
sequencing of the Neisseria meningitidis genome and bioinformatics
analysis allowed the identification of 570 potential antigens, of which
350 were expressed in E. coli and tested for immunogenicity in mice.
Confirmation of surface exposure and bactericidal activity led to the
selection of 3 proteins: Neisseria adhesin A, factor H binding protein
and Neisseria heparin-binding antigen, which are combined with the
outer membrane vesicle component NZ PorinA 1.4 in the final vac-
cine formulation (16). Novartis has completed clinical trials of 4CmenB
in 1,712 adults and adolescents, 250 children and 5,850 infants with
a variety of vaccination schedules and has compiled an extensive clin-
ical database. 4CMenB demonstrated a protective immune response
across all age groups, with, for example, 95-100% of infants having
sufficient bactericidal titers after a 2-, 4-, 6- and 12-month dosing
schedule alongside routine vaccines. Novartis has also validated and
standardized the Meningococcal Antigen Typing System (MATS), an
ELISA test which gives predictive coverage estimates for 4CMenB, by
examining the presence of antigens used in 4CMenB in circulating
meningitis strains. MATS results from 8 European countries, Australia,
the U.S., Brazil and Canada on over 2,000 MenB strains estimate that
66 to 91% would be covered by 4CMenB (17). In November 2012, the
Committee for Medicinal Products for Human Use (CHMP) adopted a
SMR 2013 W.K. Alderton et al.
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Figure 4. Development of the LEDGIN class of inhibitors; from the hit CX-05168 to the lead CX-14442.
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2013 after the E.U. commission provided endorsement. Therefore, the
potential for broad protection from the last of the major causes of
childhood bacterial meningitis is now available.
RTS,S: the first licensed malaria vaccine?
Professor Eleanor Riley, London School of Hygiene and Tropical Med-
icine, U.K., described the burden of disease for malaria; there are an-
nually 216 million clinical episodes and 655,000 deaths in 2010
predominantly in children under 5 years in sub-Saharan Africa (WHO
figures). However, a recent paper in The Lancet (18) cited 1.2 million
malaria deaths in 2010 due to a higher incidence in Asia and in adults
than have been estimated by the WHO. There is also rising awareness
of increasing malaria deaths in Southeast Asia due to Plasmodium
knowlesi, an emerging zoonotic species of malaria with high fatality
rates. Patterns of malarial disease show severe malaria mainly in chil-
dren under 10 years of age, but then a very large adult population
with mild or asymptomatic disease. The most frequent causes of hos-
pitalization are severe anemia, cerebral malaria and severe respiratory
distress. Professor Riley described the lifecycle of Plasmodium falci-
parum, a protozoan parasite that is transmitted by the female mos-
quito. Sporozoites released from the salivary glands of the mosquito
enter the human bloodstream during feeding, quickly invading liver
cells, where they undergo asexual multiplication. This results in mero-
zoites, which are released from the hepatocytes and invade more red
blood cells (RBCs). There is then an obligate sexual reproduction in
the mosquito which leads to very high genetic diversity of the parasite.
Sequestration and rosetting (clumping of cells) also occur, whereby
the infected RBCs adhere tightly to endothelial cells in the vascula-
ture, leading to obstruction of the microcirculation, and result in dys-
function of multiple organs, such as brain, lungs and also the placenta
during pregnancy. There are several points during the lifecycle at
which malarial vaccination intervention can be directed; the pre-ery-
throcytic stage, the blood stage and during transmission or sexual re-
production,  and  all  of  these  are  being  investigated  for  vaccine
development. However, malaria vaccine development has proved to
be very challenging and as yet there is no licensed, clinically effective
malaria vaccine. The complex life cycle of malaria parasites and the
stage-specific nature of immune responses pose great challenges for
vaccine development and there are also no good animal models for
the disease. There are no malaria “strains”, since every infection is ge-
netically unique due to extensive polymorphism; clinical disease is
typically associated with infection by a new parasite genotype. Also,
conserved antigens/regions tend to be poorly immunogenic and
many antigens are highly polymorphic, especially those expressed at
the surface of the parasite. In the last 40 years, all vaccine types have
been tried, and synthetic peptides and DNA vaccines proved unsuc-
cessful. Live, attenuated vaccines, virally vectored vaccines and re-
combinant proteins are all in clinical trials or have been tested in
humans. For example, the most effective vaccine to date is attenu-
ated (irradiated) whole sporozoites; this approach is under develop-
ment by Sanaria (www.sanaria.com). The vaccine is administered via
bites of infected mosquitoes giving 100% protection over 12 weeks
against homologous and heterologous strains of parasites, with pro-
tection up to 42 weeks in some individuals. Drug-attenuated sporo-
zoite infection and ultra-low-dose blood-stage infection are also being
studied. RTS,S has the potential to be the first licensed malaria vac-
cine and is in development by GlaxoSmithKline and the Walter Reed
Army Institute of Research with funding also from the Bill & Melinda
Gates  Foundation  via  the  PATH  Malaria  Vaccine  Initiative
(http://www.malariavaccine.org). RTS,S is a  recombinant chimeric
protein representing the repetitive B cell (R) and T cell (T) epitopes of
the CS protein of the 3D7 genotype of P. falciparum linked to hepati-
tis B virus surface (S) antigen. Extensive phase I and II trials have been
carried out and the vaccine is currently in phase III. In adult males in
the Gambia, the vaccine efficiency was found to be 34% over 16 weeks
of surveillance, while in a long-term follow-up study in children in
Mozambique the vaccine efficiency against mild malaria episodes was
29% and the efficiency against severe malaria was 44%. The vaccine
was still effective in the second year post-vaccination via an unknown
mechanism. The phase III trial is a multicenter study at 11 sites with
16,000 children vaccinated at 6-12 weeks or 5-17 months on a 0-, 1-
and 2-month vaccination schedule. The initial results were promis-
ing of partial efficacy, with 50.4% efficacy against clinical malaria
episodes in the 14 months after the first dose of vaccine (19). How-
ever, next-generation vaccines need to include blood-stage antigens
to mop up breakthrough infections and a transmission blocking com-
ponent, and complementation of RTS,S may be the most efficient way
to achieve this. However, most blood-stage vaccines have failed; at
least 10 candidate vaccines were discontinued at or before phase II
trials and only 3 of the 20 remaining candidates have so far reached
phase IIb. There is hope, however, with the recent discovery of basigin
as an essential receptor of which the parasite ligand (PfRH5) is rela-
tively invariant (20), which may prove successful in combating this
deadly disease in combination with RTS,S.
CONCLUSIONS
Resistance of microorganisms to the current arsenal of clinical anti-
infective agents continues to rise, leading to the threat of untreatable
infections. “Big Pharma” research into new antibacterials has, unfor-
tunately, concomitantly declined due to the general challenges of an-
tibiotic  research,  the  low  return  on  investment  and  a  difficult
regulatory environment. These themes have, to some extent, been
mirrored in the antiviral and antiinfective vaccinology fields. However,
more recently the “green shoots” of a new era may be sprouting.
Firstly, multidisciplinary research groups straddling academia and 
industry have appeared offering creative solutions to target identifi-
cation, validation and drug discovery. Secondly, international colla  -
borations  have  led  to  sustained  progress  in  drug  and  vaccine
development. Thirdly, pragmatic solutions to the current mismatch
and complexity of regulatory authority requirements for new antiin-
fective agents are on the near-term horizon through European-led
initiatives such as IMI. The challenges, solutions and progress shared
in this SMR meeting provided encouraging examples of prevention
and treatment developments and a welcome optimistic counter to
the near-future, worldwide threat of pan-resistant microorganisms.
DISCLOSURES
W.K. Alderton is an employee of Abcodia, S.P. Collingwood is an em-
ployee of Novartis and D. Pryde is an employee of Pfizer. R.J. Ander-
son states no conflicts of interest.
W.K. Alderton et al. SMR 2013
353 THOMSON REUTERS – Drugs of the Future 2013, 38(5)REFERENCES
1. http://www.ecdc.europa.eu/en/publications/Publications/Forms/
ECDC_DispForm.aspx?ID=998
2. El Salabi, A., Walsh T.R., Chouchani, C. Extended spectrum b-lactamases,
carbapenemases and mobile genetic elements responsible for antibiotics
resistance in Gram-negative bacteria. Crit Rev Microbiol 2013, 39(2): 113-
22.
3. http://apps.who.int/iris/bitstream/10665/44812/1/9789241503181_
eng.pdf
4. Tyrrell, J., Warn, P., Payne, L. et al. Inverse relationship between patho-
genicity  and  NDM-1  carriage  in  Escherichia  coli.  22nd Eur  Congr  Clin
Microbiol Infect Dis (ECCMID) (March 21-April 3, London) 2012.
5. Rex,  J.H.,  Eisenstein,  B.I.,  Alder,  J.  et  al.  A  comprehensive  regulatory
framework to address unmet need for new antibacterial treatments. Lancet
Infect Dis 2013, 13(3): 269-275.
6. Pethe K., Sequeira P.C., Agarwalla S. et al. A chemical genetic screen in
Mycobacterium  tuberculosis  identifies  carbon-source-dependent  growth
inhibitors devoid of in vivo efficacy. Nat Commun 2010, 1: 57.
7. Johansson, P.-O., Bäck, M., Kvarnström, I. et al. Potent inhibitors of the
hepatitis C virus NS3 protease: Use of a novel P2 cyclopentane-derived
template. Bioorg Med Chem 2006, 14(15): 5136-51.
8. Bäck, M., Johansson, P.-O., Wångsell, F. et al. Novel potent macrocyclic
inhibitors of the hepatitis C virus NS3 protease: Use of cyclopentane and
cyclopentene P2-motifs. Bioorg Med Chem 2007, 15(22): 7184-202.
9. Saalau-Bethell, S.M., Woodhead, A.J., Chessari, G. et al. Discovery of an
allosteric mechanism for the regulation of HCV NS3 protein function. Nat
Chem Biol 2012, 8(11): 920-5.
10. Ding, S.C., Kohlway, A.S., Pyle, A.M. Unmasking the active helicase con-
formation of nonstructural protein 3 from hepatitis C virus. J Virol 2011,
85(9): 4343-53.
11. Cherepanov, P., Maertens, G., Proost, P. et al. HIV-1 Integrase forms stable
tetramers and associates with LEDGF/p75 protein in human cells. J Biol
Chem 2003, 278(1): 372-81.
12. Taltynov, O., Desimmie, B.A., Demeulemeester, J. et al. Cellular cofactors
of lentiviral integrase: From target validation to drug discovery. Mol Biol Int
2012, 2012: 863405.
13. Christ, F., Voet, A., Marchand, A. et al. Rational design of small-molecule
inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat
Chem Biol 2010, 6(6): 442-8.
14. Christ, F., Shaw, S., Demeulemeester, J. et al. Small-molecule inhibitors of
the LEDGF/p75 binding site of integrase block HIV replication and modu-
late  integrase  multimerization.  Antimicrob  Agents  Chemother  2012,
56(8): 4365-74.
15. Demeulemeester,  J.,  Tintori,  C.,  Botta,  M.,  Debyser,  Z.,  Christ,  F.
Development of an AlphaScreen-based HIV-1 integrase dimerization assay
for discovery of novel allosteric inhibitors. J Biomol Screen 2012, 17(5): 618-
28.
16. Donnelly, J., Medini, D., Boccadifuoco, G. et al. Qualitative and quantita-
tive assessment of meningococcal antigens to evaluate the potential strain
coverage  of  protein-based  vaccines.  Proc  Natl  Acad  Sci  U  S  A  2010,
107(45): 19490-5.
17. Vogel, U., Taha, M.K., Vazquez, J.A. et al. Predicted strain coverage of a
meningococcal multicomponent vaccine (4CMenB) in Europe: A qualitative
and quantitative assessment. Lancet Infect Dis 2013, Epub ahead of print.
18. Murray, C.J., Rosenfeld, L.C., Lim, S.S. et al. Global malaria mortality
between 1980 and 2010: A systematic analysis. Lancet 2012, 379(9814):
413-31.
19. Agnandji, S.T., Lell B., Soulanoudjinger, S.S. et al.; RTS,S Clinical Trials
Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in
African children. N Engl J Med 2011, 365(20): 1863-75.
20. Crosnier, C., Bustamante, L.Y., Bartholdson, S.J. et al. Basigin is a recep-
tor essential for erythrocyte invasion by Plasmodium falciparum. Nature
2011, 480(7378): 534-7.
C
SMR 2013 W.K. Alderton et al.
354 THOMSON REUTERS – Drugs of the Future 2013, 38(5)